Personalized approaches informed by ethnic-specific disease biology and clinical experience will be crucial for effectively bridging the current knowledge gaps in PSMA-targeted RLT for Asian prostate cancer patients. This evidence concerns the gene FOLH1 and Familial prostate cancer.